Becton Dickinson Basic EPS 2010-2024 | BDX
Becton Dickinson annual/quarterly basic eps history and growth rate from 2010 to 2024. Basic eps can be defined as a company's net earnings or losses attributable to common shareholders per basic share basis.
- Becton Dickinson basic eps for the quarter ending September 30, 2024 was $1.45, a 314.29% increase year-over-year.
- Becton Dickinson basic eps for the twelve months ending September 30, 2024 was $5.95, a 19.72% increase year-over-year.
- Becton Dickinson annual basic eps for 2024 was $0.006B, a 19.92% increase from 2023.
- Becton Dickinson annual basic eps for 2023 was $0.005B, a 16.19% decline from 2022.
- Becton Dickinson annual basic eps for 2022 was $0.006B, a 14.31% decline from 2021.
| Becton Dickinson Annual Basic EPS |
| 2024 |
$5.96 |
| 2023 |
$4.97 |
| 2022 |
$5.93 |
| 2021 |
$6.92 |
| 2020 |
$2.75 |
| 2019 |
$4.01 |
| 2018 |
$0.62 |
| 2017 |
$4.70 |
| 2016 |
$4.59 |
| 2015 |
$3.43 |
| 2014 |
$6.13 |
| 2013 |
$6.63 |
| 2012 |
$5.69 |
| 2011 |
$5.75 |
| 2010 |
$5.62 |
| 2009 |
$5.12 |
| Becton Dickinson Quarterly Basic EPS |
| 2024-09-30 |
$1.45 |
| 2024-06-30 |
$1.68 |
| 2024-03-31 |
$1.85 |
| 2023-12-31 |
$0.97 |
| 2023-09-30 |
$0.35 |
| 2023-06-30 |
$1.37 |
| 2023-03-31 |
$1.54 |
| 2022-12-31 |
$1.71 |
| 2022-09-30 |
$0.94 |
| 2022-06-30 |
$1.18 |
| 2022-03-31 |
$1.51 |
| 2021-12-31 |
$2.30 |
| 2021-09-30 |
$0.86 |
| 2021-06-30 |
$1.73 |
| 2021-03-31 |
$0.95 |
| 2020-12-31 |
$3.38 |
| 2020-09-30 |
$0.36 |
| 2020-06-30 |
$0.98 |
| 2020-03-31 |
$0.53 |
| 2019-12-31 |
$0.88 |
| 2019-09-30 |
$0.46 |
| 2019-06-30 |
$1.53 |
| 2019-03-31 |
$-0.07 |
| 2018-12-31 |
$2.09 |
| 2018-09-30 |
$-0.51 |
| 2018-06-30 |
$2.08 |
| 2018-03-31 |
$-0.19 |
| 2017-12-31 |
$-0.76 |
| 2017-09-30 |
$1.20 |
| 2017-06-30 |
$-0.75 |
| 2017-03-31 |
$1.61 |
| 2016-12-31 |
$2.64 |
| 2016-09-30 |
$0.09 |
| 2016-06-30 |
$1.83 |
| 2016-03-31 |
$1.59 |
| 2015-12-31 |
$1.08 |
| 2015-09-30 |
$0.81 |
| 2015-06-30 |
$0.30 |
| 2015-03-31 |
$1.10 |
| 2014-12-31 |
$1.22 |
| 2014-09-30 |
$1.56 |
| 2014-06-30 |
$1.69 |
| 2014-03-31 |
$1.48 |
| 2013-12-31 |
$1.40 |
| 2013-09-30 |
$0.48 |
| 2013-06-30 |
$1.55 |
| 2013-03-31 |
$1.42 |
| 2012-12-31 |
$3.18 |
| 2012-09-30 |
$1.43 |
| 2012-06-30 |
$1.62 |
| 2012-03-31 |
$1.41 |
| 2011-12-31 |
$1.23 |
| 2011-09-30 |
$1.38 |
| 2011-06-30 |
$1.57 |
| 2011-03-31 |
$1.41 |
| 2010-12-31 |
$1.39 |
| 2010-09-30 |
$1.71 |
| 2010-06-30 |
$1.32 |
| 2010-03-31 |
$1.26 |
| 2009-12-31 |
$1.33 |
| 2009-09-30 |
$1.32 |
| 2009-06-30 |
$1.42 |
| 2009-03-31 |
$1.09 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical & Dental Supplies |
$66.954B |
$20.178B |
|
Becton, Dickinson and Company, is a medical technology company engaged principally in the development, manufacture and sale of medical devices, instrument systems and reagents. BD's operations consisted of three business segments: BD Medical, BD Diagnostics and BD Biosciences. The company's organizational structure was realigned to form two principal business segments: BD Medical, BD Life Sciences and BD Interventional. BD Medical: BD Medical's major product lines include needles, syringes and intravenous catheters for medication delivery and generic prefilled injectables. BD Life Sciences - BD Diagnostics provides products for the safe collection and transport of diagnostics specimens to detect a broad range of infectious diseases, healthcare-associated infections and cancer. BD Biosciences produces research and clinical tools that facilitate the study of cells to gain a better understanding of normal and disease processes. With the acquisition of C.R. Bard, BD added a new segment - BD Interventional.
|
